Fujita Hiromasa
Department of Surgery, Kurume University School of Medicine, Kurume, Fukuoka, Japan.
Ann Thorac Cardiovasc Surg. 2013;19(6):409-15. doi: 10.5761/atcs.ra.13-00085. Epub 2013 Nov 27.
The history of esophageal surgery in Japan can be divided into three periods, an era of safety from 1930 to 1980, an era of radicality from 1980 to 2000, and the era of quality of life (QOL) from 2000 to the present. The treatment for T4 cancers of the thoracic esophagus has also changed over time from preoperative radiotherapy, combined resection of the neighboring organs with esophagectomy, and to definitive chemoradiotherapy (dCRT) with salvage surgery. At present, almost all patients with an unresectable T4 esophageal cancer receives dCRT. However, there are many patients with a residual or recurrent tumor after dCRT. Salvage surgery for such patients often results in incomplete resection of the tumor because the tumor involves the trachea and/or aorta. New techniques to enable the resection of such neighboring organs even during salvage surgery are needed. In the future, the mainstay of treatment for esophageal cancer will be CRT with the foreseeable progress in new drugs and new techniques of radiotherapy. Surgery will be indicated for a local failure after CRT, while combined resection of the neighboring organs will be necessary to treat a local failure after CRT for T4 cancers. New surgical techniques have to be developed through some application of new devices and equipment.
1930年至1980年的安全时代、1980年至2000年的根治时代以及2000年至今的生活质量(QOL)时代。胸段食管癌T4期癌症的治疗也随着时间的推移而发生了变化,从术前放疗、与食管切除术联合切除邻近器官,发展到采用挽救性手术的根治性放化疗(dCRT)。目前,几乎所有无法切除的T4期食管癌患者都接受dCRT。然而,有许多患者在dCRT后出现肿瘤残留或复发。对于这类患者,挽救性手术往往导致肿瘤切除不完全,因为肿瘤累及气管和/或主动脉。需要新的技术,以便即使在挽救性手术期间也能切除此类邻近器官。未来,随着新药和放疗新技术的可预见进展,食管癌治疗的主要手段将是放化疗。对于放化疗后出现局部失败的情况,将需要进行手术,而对于T4期癌症放化疗后出现局部失败的情况,则需要联合切除邻近器官。必须通过一些新设备和器械的应用来开发新的手术技术。